ArticleThe Journal of antimicrobial chemotherapy2022
Characteristics of community-acquired carbapenem-resistant Enterobacterales.
Article in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Hidden in the community: poly-clonal spread of KPC- or NDM-producing Klebsiella pneumoniae revealed by whole-genome sequencing in Southeastern Brazil.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Human Cases of Carbapenemase-Producing Escherichia coli Linked to Spread Between Animals and the Environment in a Veterinary Facility-Massachusetts, USA, 2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Genomic Epidemiology of ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Community-associated Carbapenem-Resistant Organism Case Investigations in New York City.Open forum infectious diseases · 2025Article
- A network analysis of carbapenem-resistant Klebsiella pneumoniae among healthcare facilities.Scientific reports · 2025Observational
- Plasmid Dissemination in Multispecies Carbapenemase-Producing Enterobacterales Outbreaks Involving Clinical and Environmental Strains: A Narrative Review.Microorganisms · 2025Review
- The Prevalence of Multidrug Resistance in Enterobacterales Is Higher in Patients Undergoing Hematopoietic Stem Cell Transplantation.Open forum infectious diseases · 2025Article
- Population-Based Study of Emergence and Spread of Escherichia coli Producing OXA-48-Like Carbapenemases, Israel, 2007-2023.Emerging infectious diseases · 2025Article
- Prevalence of rectal carbapenem resistant Enterobacterales carriage among patients attending healthcare facilities in Ibadan, Nigeria: a descriptive study.BMC infectious diseases · 2024Article
- Molecular characterization and descriptive analysis of carbapenemase-producing Gram-negative rod infections in Bogota, Colombia.Microbiology spectrum · 2024Article
- Article
- Molecular Epidemiology of Carbapenem-ResistantInternational journal of molecular sciences · 2024Article
- Risk Factors and Outcomes of Community-Acquired Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Observational
- Trends in Incidence of Carbapenem-Resistant Enterobacterales in 7 US Sites, 2016─2020.Open forum infectious diseases · 2023Article
- Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- The distribution characteristics of global blaOXA-carrying Klebsiella pneumoniae.BMC infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCommunity-acquired carbapenem-resistant Enterobacterales (CA-CRE) are an important threat.
methodsIn CRACKLE-2, we defined patients with CA-CRE as admitted from home, without pre-existing conditions, and a positive culture within 48 h of admission. Healthcare-associated CRE (HA-CRE) were those with the lowest likelihood of community acquisition, not admitted from home and cultured >48 h after admission. Specific genetic markers in carbapenemase-producing Klebsiella pneumoniae were evaluated through random forest modelling.
resultsCA-CRE and HA-CRE were detected in 83 (10%) and 208 (26%) of 807 patients. No significant differences were observed in bacterial species or strain type distribution. K. pneumoniae (204/291, 70%) was the most common CRE species, of these 184/204 (90%) were carbapenemase producers (CPKP). The top three genetic markers in random forest models were kpi_SA15, fimE, and kpfC. Of these, kpi_SA15 (which encodes a chaperone/usher system) was positively associated (OR 3.14, 95% CI 1.13-8.87, P = 0.026), and kpfC negatively associated (OR 0.21, 95% CI 0.05-0.72, P = 0.015) with CA-CPKP.
conclusionsTen percent of CDC-defined CRE were CA. The true proportion of CA-CRE in hospitalized patients is likely lower as patients may have had unrecorded prior healthcare exposure. The kpi_SA15 operon was associated with the CA phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.